Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Total Non-Current Liabilities: 2022-2023

  • Therapeutics' Total Non-Current Liabilities was N/A to $32.9 million in Q1 2023 from the same period last year, while for Mar 2023 it was $32.9 million, marking a year-over-year change of. This contributed to the annual value of $14.8 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q1 2023, Therapeutics' Total Non-Current Liabilities is $32.9 million, which was up 122.42% from $14.8 million recorded in Q4 2022.
  • Therapeutics' Total Non-Current Liabilities' 5-year high stood at $32.9 million during Q1 2023, with a 5-year trough of $14.8 million in Q4 2022.
  • For the 2-year period, Therapeutics' Total Non-Current Liabilities averaged around $21.2 million, with its median value being $16.0 million (2022).